Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.37 |
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19184811 | 0.87 | EPHX2 (0.38) | MAPTEPHX2CYP1A2TDP1EPHX1 | |
| SCHEMBL4569257 | 0.82 | EPHX2 (0.44) | EPHX2CYP1A2TDP1EPHX1KDM4E | |
| SCHEMBL27053463 | 0.77 | EPHX2 (0.42) | EPHX2CYP1A2TDP1EPHX1KDM4E | |
| SCHEMBL21579250 | 0.76 | CHRM3 (0.36) | TDP1ALDH1A1 | |
| SCHEMBL19184997 | 0.74 | EPHX2 (0.37) | MAPTEPHX2KDM4EUSP2ALDH1A1 | |
| SCHEMBL19184807 | 0.74 | GNAI3 (0.39) | MAPTEPHX2KDM4EUSP2ALDH1A1 | |
| SCHEMBL4572154 | 0.74 | MAPT (0.44) | MAPTEPHX2CYP1A2TDP1EPHX1 | |
| SCHEMBL13881065 | 0.74 | EPHX2 (0.41) | MAPTEPHX2CYP1A2TDP1PIK3CD | |
| SCHEMBL23134531 | 0.73 | CYP1A2 (0.46) | EPHX2CYP1A2TDP1EPHX1KDM4E | |
| SCHEMBL18855198 | 0.73 | EPHX2 (0.46) | MAPTEPHX2CYP1A2TDP1PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180042902-A1 | Heterocyclic Compounds and Uses Thereof | INTELLIKINE, LLC | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180042902-A1 | Heterocyclic Compounds and Uses Thereof | PIK3CA, PIK3CD, PIK3CB | MAPT 2704/4885EPHX2 1456/4885CYP1A2 1496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.